Final overall survival analysis of the phase 3 HERITAGE study demonstrates equivalence of trastuzumab-dkst to trastuzumab in HER2-positive metastatic breast cancer

zu Verbundenen Objekten

Standort
Deutsche Nationalbibliothek Frankfurt am Main
ISSN
1573-7217
Umfang
Online-Ressource
Sprache
Englisch
Anmerkungen
online resource.

Erschienen in
Final overall survival analysis of the phase 3 HERITAGE study demonstrates equivalence of trastuzumab-dkst to trastuzumab in HER2-positive metastatic breast cancer ; volume:188 ; number:2 ; day:14 ; month:6 ; year:2021 ; pages:369-377 ; date:7.2021
Breast cancer research and treatment ; 188, Heft 2 (14.6.2021), 369-377, 7.2021

Urheber
Rugo, Hope S.
Pennella, Eduardo J.
Gopalakrishnan, Unmesh
Hernandez-Bronchud, Miguel
Herson, Jay
Koch, Hans Friedrich
Loganathan, Subramanian
Deodhar, Sarika
Marwah, Ashwani
Manikhas, Alexey
Bondarenko, Igor
Mukhametshina, Guzel
Nemsadze, Gia
Parra, Joseph D.
Abesamis-Tiambeng, Maria Luisa T.
Baramidze, Kakhaber
Akewanlop, Charuwan
Vynnychenko, Ihor
Sriuranpong, Virote
Mamillapalli, Gopichand
Roy, Sirshendu
Yanez Ruiz, Eduardo Patricio
Barve, Abhijit
Fuentes-Alburo, Adolfo
Waller, Cornelius
Beteiligte Personen und Organisationen
SpringerLink (Online service)

DOI
10.1007/s10549-021-06197-5
URN
urn:nbn:de:101:1-2021101521150773783482
Rechteinformation
Open Access; Der Zugriff auf das Objekt ist unbeschränkt möglich.
Letzte Aktualisierung
15.08.2025, 07:22 MESZ

Datenpartner

Dieses Objekt wird bereitgestellt von:
Deutsche Nationalbibliothek. Bei Fragen zum Objekt wenden Sie sich bitte an den Datenpartner.
Original beim Datenpartner anzeigen

Beteiligte

  • Rugo, Hope S.
  • Pennella, Eduardo J.
  • Gopalakrishnan, Unmesh
  • Hernandez-Bronchud, Miguel
  • Herson, Jay
  • Koch, Hans Friedrich
  • Loganathan, Subramanian
  • Deodhar, Sarika
  • Marwah, Ashwani
  • Manikhas, Alexey
  • Bondarenko, Igor
  • Mukhametshina, Guzel
  • Nemsadze, Gia
  • Parra, Joseph D.
  • Abesamis-Tiambeng, Maria Luisa T.
  • Baramidze, Kakhaber
  • Akewanlop, Charuwan
  • Vynnychenko, Ihor
  • Sriuranpong, Virote
  • Mamillapalli, Gopichand
  • Roy, Sirshendu
  • Yanez Ruiz, Eduardo Patricio
  • Barve, Abhijit
  • Fuentes-Alburo, Adolfo
  • Waller, Cornelius
  • SpringerLink (Online service)

Ähnliche Objekte (12)

Final overall survival analysis of the phase 3 HERITAGE study demonstrates equivalence of trastuzumab-dkst to trastuzumab in HER2-positive metastatic breast cancer

Final overall survival analysis of the phase 3 HERITAGE study demonstrates equivalence of trastuzumab-dkst to trastuzumab in HER2-positive metastatic breast cancer

Trastuzumab Deruxtecan: A Quantum Leap in HER2‑Positive Breast Cancer

Trastuzumab Deruxtecan: A Quantum Leap in HER2‑Positive Breast Cancer

Genomic characteristics of trastuzumab-resistant Her2-positive metastatic breast cancer

Genomic characteristics of trastuzumab-resistant Her2-positive metastatic breast cancer

CMTM6 overexpression confers trastuzumab resistance in HER2-positive breast cancer

CMTM6 overexpression confers trastuzumab resistance in HER2-positive breast cancer

Second-Line Treatment of HER2-Positive Salivary Gland Tumor: Ado-Trastuzumab Emtansine (T-DM1) after Progression on Trastuzumab

Second-Line Treatment of HER2-Positive Salivary Gland Tumor: Ado-Trastuzumab Emtansine (T-DM1) after Progression on Trastuzumab

Comparison of trastuzumab emtansine, trastuzumab deruxtecan, and disitamab vedotin in a multiresistant HER2-positive breast cancer lung metastasis model

Comparison of trastuzumab emtansine, trastuzumab deruxtecan, and disitamab vedotin in a multiresistant HER2-positive breast cancer lung metastasis model

Correction: CMTM6 overexpression confers trastuzumab resistance in HER2‑positive breast cancer

Correction: CMTM6 overexpression confers trastuzumab resistance in HER2‑positive breast cancer

Trastuzumab deruxtecan versus trastuzumab emtansine in HER2-positive metastatic breast cancer: long-term survival analysis of the DESTINY-Breast03 trial

Trastuzumab deruxtecan versus trastuzumab emtansine in HER2-positive metastatic breast cancer: long-term survival analysis of the DESTINY-Breast03 trial

Vasculogenic mimicry is associated with trastuzumab resistance of HER2-positive breast cancer

Vasculogenic mimicry is associated with trastuzumab resistance of HER2-positive breast cancer

Correction to: Population pharmacokinetics of PF‑05280014 (a trastuzumab biosimilar) and reference trastuzumab (Herceptin®) in patients with HER2‑positive metastatic breast cancer

Correction to: Population pharmacokinetics of PF‑05280014 (a trastuzumab biosimilar) and reference trastuzumab (Herceptin®) in patients with HER2‑positive metastatic breast cancer

Biomarker analysis of the NeoSphere study: pertuzumab, trastuzumab, and docetaxel versus trastuzumab plus docetaxel, pertuzumab plus trastuzumab, or pertuzumab plus docetaxel for the neoadjuvant treatment of HER2-positive breast cancer

Biomarker analysis of the NeoSphere study: pertuzumab, trastuzumab, and docetaxel versus trastuzumab plus docetaxel, pertuzumab plus trastuzumab, or pertuzumab plus docetaxel for the neoadjuvant treatment of HER2-positive breast cancer

Metabolic heterogeneity affects trastuzumab response and survival in HER2-positive advanced gastric cancer

Metabolic heterogeneity affects trastuzumab response and survival in HER2-positive advanced gastric cancer

Verbundene Objekte